The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial

Document Type : Original Research Article

Authors

1 Student Research Committee, Department of Modern Sciences & Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

3 Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran

5 Pharmaceutical Research Center, Department of Medicinal Chemistry, Mashhad University of Medical Sciences, Mashhad, Iran

6 Department of Medical Biotechnology, Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract


Objective: Diabetes mellitus is defined as a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both or insulin resistance. Curcumin inhibits NF-κB signaling pathway. The aim of this study is evaluation of the effect of Nano-curcumin on HbA1C, fast blood glucose and lipid profile in diabetic patients.
Materials and Methods: Seventy type-2 diabetic patients (fasting blood glucose (FBG) ≥ 126 mg/dL or 2-hr postprandial blood glucose ≥200 mg/dl) randomly receivedeither Curcumin (as nano-micelle 80 mg/day) or placebo for 3 months in a double blind randomized clinical trial. Fasting blood glucose, HbA1C, and lipids profile were checked before and after the intervention. Data analyses, including parametric and nonparametric tests were done using the SPSS 11.5 software. A p value < 0.05 was regarded as statistically significant. (RCT registration code: IRCT2013081114330N1)
Results: Mean age, BMI, FBG, total cholesterol (TC), triglyceride (TG), LDL, HDL, HbA1c , and  sex and had no significant difference at the baseline between the groups. In Nano-curcumin group, a significant decrease was found in HbA1C, FBG, TG, and BMI comparing results of each subject before and after the treatment (p<0.05).
By comparing pre- and post-treatment values among the groups, HbA1c, eAG, LDL-C, and BMI variables showed significant differences (p<0.05).   
Conclusion: These findings suggest an HbA1c lowering effect for Nano-curcumin in type-2 diabetes; also, it is partially decrease in serum LDL-C and BMI.

Keywords

Main Subjects

References

Aggarwal BB, Harikumar KB. 2009. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol, 41: 40-59.
Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB, Ernie S.2008.The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones, 40: 201-210.
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 2007. Bioavailability of curcumin: problems and promises. Mol Pharm, 46: 807-818.
Association AD. 2013.Diagnosis and classification of diabetes mellitus. Diabetes care,36: S67-S74.
Chainani-WuN. 2003.Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med, 91: 161-168.
Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. 2012.Curcumin extract for prevention of type 2 diabetes. Diabetes Care, 35: 2121-2127.
Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. 2014.Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem, 25: 144-150.
Freitas AC, Pinheiro AL, Miranda P, Thiers FA, Vieira AL. 2001. Assessment of anti-inflammatory effect of 830nm laser light using C-reactive protein levels. Braz Dent J, 12: 187-190.
Gao B, Bataller R. 2011.Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology, 141: 1572-1585.
Garodia P, Ichikawa H, Malani N, Sethi G, Aggarwal BB.2007.From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inflammation and cancer. J Soc Integr Oncol, 5: 25-37.
Ghorbani Z, Hekmatdoost A, Mirmiran P. 2014.Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin. Int J Endocrinol Metab, 12: e18081.
Gupta SC, Patchva S, Aggarwal BB.2013. Therapeutic roles of curcumin: lessons learned from clinical trials.AAPS J, 15: 195-218.
Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. 2008. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci, 65: 1631-1652.
Howles PN.2010.Cholesterol absorption and metabolism. Methods Mol Biol, 602: 157-179.
Hsu CH, Cheng AL. 2007.Clinical studies with curcumin. Adv Exp Med Biol, 595: 471-480.
Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S, Dontu G, Wicha MS. 2010.Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat, 122: 777-785.
Kang Q, Chen A. 2009.Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br J Pharmacol, 157: 1354-1367.
Kazemi-Bajestani SM, Ghayour-Mobarhan M, Ebrahimi M, Moohebati M, Esmaeili HA, Ferns GA.2007.C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease. Clin Lab, 53: 49-56.
Larejani B, Zahedi F. 2001.Epidemiology of diabetes mellitus in Iran. Ir J Diabetes Met, 1: 1-8.
Liu J, Chen S, Lv L, Song L, Guo S, Huang S. 2013.Recent progress in studying curcumin and its nano-preparations for cancer therapy. Curr pharm des, 19: 1974-1993.
Menon VP, Sudheer AR.2007. Antioxidant and anti-inflammatory properties of curcumin. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, pp. 105-125, Texas, Springer.
Nezhad MZ, Ghanbari P, Shahryari B, Aghasadeghi K.2009. C-Reactive Protein in Angiographically Documented Stable Coronary Disease. Ir Cardiovas Res J, 3:97-101.
Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns GA. 2013.Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res, 27: 374-379.
Muthenna P, Suryanarayana P, Gunda SK, Petrash JM, Reddy GB. 2009."Inhibition of aldose reductase by dietary antioxidant curcumin: mechanism of inhibition, specificity and significance. FEBS Lett, 583: 3637-3642.
Na LX, Zhang YL, Li Y, Liu LY, Li R, Kong T, Sun CH. 2011.Curcumin improves insulin resistance in skeletal muscle of rats. Nutr Metab Cardiovasc Dis, 217: 526-533.
Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. 2007.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab, 92: 194-205.
Neerati P, Devde R, Gangi AK.2014.Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus. Phytother Res, 28: 1796-1800.
Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K, Kitahara M. 2005. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem, 53: 959-963.
Pekkanen J, Tuomilehto J, Qiao Q, Jousilahti P, Lindström J, Group DS. 1999.Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet, 354: 617-621.
Pettitt DJ, Talton J, Dabelea D, Divers J, Imperatore G, Lawrence JM, Liese AD, Linder B, Mayer-Davis EJ, Pihoker C, Saydah SH, Standiford DA, Hamman RF; SEARCH for Diabetes in Youth Study Group. 2014.Prevalence of Diabetes in US Youth in 2009: The SEARCH for Diabetes in Youth Study. Diabetes care, 37: 402-408.
Rahimi HR, Jaafari MR, Mohammadpour AH, Abnous K, Ghayour Mobarhan M,Ramezanzadeh E, Mousavi F,Kazemi Oskuee R. 2015. Curcumin: Reintroduced Therapeutic Agent from Traditional Medicine for Alcoholic Liver Disease. Asia Pacific J Med Tox, 4: 25-30.
Rahimi HR, Kazemi Oskuee R. 2014. Curcumin From Traditional Iranian Medicine to Molecular Medicine. Razavi Int J Med, 2: 3-4.
Saini V. 2010.Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes, 1: 68-75.
Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V, Aggarwal BB.2007). Curcumin, demethoxycurcumin, bisdemethoxycurcumin,tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis, 28: 1765-1773.
Santel T, Pflug G, Hemdan NY, Schäfer A, Hollenbach M, Buchold M, Hintersdorf A, Lindner I, Otto A, Bigl M, Oerlecke I, Hutschenreuther A, Sack U, Huse K, Groth M, Birkemeyer C, Schellenberger W, Gebhardt R, Platzer M, Weiss T, Vijayalakshmi MA, Krüger M, Birkenmeier G.2008.Curcumin inhibits glyoxalase 1—a possible link to its anti-inflammatory and anti-tumor activity. PLoS One, 3: e3508.
Sharma S, Kulkarni SK, Chopra K. 2006. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol, 33: 940-945.
Singer DE, Nathan DM, Anderson KM, Wilson PW, Evans JC.1992.Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes, 41: 202-208.
Smithson KW, Millar DB, Jacobs LR, Gray GM. 1981. Intestinal diffusion barrier: unstirred water layer or membrane surface mucous coat?. Science, 214: 1241-1244.
Soni K, Kuttan R. 1992.Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physio Pharmacol, 36: 273-273.
Thamake SI, Raut SL, Ranjan AP, Gryczynski Z, Vishwanatha JK.2011.Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy. Nanotechnology, 22: 035101.
Venkatesha SH, Berman BM, Moudgil KD. 2011.Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis. Bioorg med chem, 19: 21-29.
Weisberg SP, Leibel R, Tortoriello DV.2008. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology, 149: 3549-3558.
Wild S, Roglic G, Green A, Sicree R, King H. 2004.Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes care, 27: 1047-1053.
Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. 2003. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care, 26: 1277-1294.
 
 
 
Avicenna Journal of Phytomedicine
Volume 6, Issue 5
September and October 2016
Pages 567-577

Files

Share

How to cite

Statistics